8-K
filed May 22, 2023, 7:59 PM ET
CIK 0001821323
debt
confidence high
sentiment neutral
materiality 0.60
Sigilon repays $16.4M Oxford loan early; files 1-for-13 reverse stock split
Sigilon Therapeutics, Inc.
- Repaid $16.4M to Oxford Finance for $20M term loan; all obligations terminated.
- Cash and marketable securities of $56.4M as of March 31 expected to fund operations into 2025.
- Stockholders approved 1-for-13 reverse stock split effective May 23, 2023.
- Directors Douglas Cole and Stephen Oesterle elected; PricewaterhouseCoopers ratified as auditor.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Sigilon Therapeutics, Inc.: Amended certificate of incorporation to effect a 1-for-13 reverse stock split (effective 2023-05-22).
- Change
- charter amendment
- Effective
- 2023-05-22
Exact text from the filing
On May 22, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to its Fifth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 (the “Common Stock”), at a ratio of 1-for-13.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sigilon Therapeutics, Inc. terminated Loan and Security Agreement with Oxford Finance LLC, as collateral agent for the Lenders valued at $16.4 million (effective 2023-05-19).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Oxford Finance LLC, as collateral agent for the Lenders
- Value
- $16.4 million
- Effective
- 2023-05-19
Exact text from the filing
On May 19, 2023, Sigilon Therapeutics, Inc. (the “Company”) voluntarily repaid all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to $16.4 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement dated as of September 2, 2020
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sigilon Therapeutics, Inc. shareholders approved Approval of an Amendment to the Company's Fifth Amended and Restated Certificate of Incorporation at the 2023-05-19 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal 2: Approval of an Amendment to the Company's Fifth Amended and Restated Certificate of Incorporation. The stockholders of the Company approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding Common Stock at any whole number ratio between, and inclusive of, one-for-eight and one-for-30. The results of the vote were as follows: For Against Abstain 28,979,926 378,323 31,717
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sigilon Therapeutics, Inc. shareholders approved Ratification of the Company’s Independent Registered Public Accounting Firm at the 2023-05-19 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal 3: Ratification of the Company’s Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2023. The results of the vote were as follows: For Against Abstain 29,313,965 43,976 32,025
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Sigilon Therapeutics, Inc. shareholders approved Election of Directors at the 2023-05-19 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-19
Exact text from the filing
Proposal 1: Election of Directors The stockholders of the Company elected the director nominees listed below to serve on the Company’s Board of Directors as members of Class III for a term of three years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non-Votes Douglas Cole, M.D. 23,459,263 3,294,129 37,031 2,599,543 Stephen Oesterle, M.D. 23,654,738 3,095,809 39,876 2,599,543
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.